Novel and emerging treatment strategies for acute myeloid leukemia

Abstract

Acute myeloid leukemia (AML) remains difficult and challenging to treat. Recognition that AML is a genomically heterogeneous disease has given rise to several new targeted therapies (eg, inhibitors of FLT3 and IDH1/2). Because the genomic landscape of AML evolves as the disease progresses, genomic testing is advised at diagnosis and at recurrence or relapse. In addition to targeted inhibitors, several emerging therapies directed at immune responses and p53 are on the horizon. Despite these advances, the 5-year overall survival rate for AML is 28.3%. The hope is that novel combinations and emerging strategies will move the survival bar higher for patients with AML in the near future.